David M. Berman - Feb 28, 2024 Form 4 Insider Report for Immunocore Holdings plc (IMCR)

Role
HEAD OF R&D
Signature
/s/ Lily Hepworth, Attorney-in-Fact
Stock symbol
IMCR
Transactions as of
Feb 28, 2024
Transactions value $
-$1,866,711
Form type
4
Date filed
3/1/2024, 04:15 PM
Previous filing
Feb 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMCR Ordinary Shares Options Exercise $637K +36.5K $17.46* 36.5K Feb 28, 2024 Direct F1
transaction IMCR Ordinary Shares Sale -$1.14M -16.9K -46.29% $67.61 19.6K Feb 28, 2024 Direct F1, F2
transaction IMCR Ordinary Shares Sale -$514K -7.47K -38.1% $68.84 12.1K Feb 28, 2024 Direct F1, F3
transaction IMCR Ordinary Shares Sale -$763K -10.9K -90.11% $69.73 1.2K Feb 28, 2024 Direct F1, F4
transaction IMCR Ordinary Shares Sale -$84.5K -1.2K -100% $70.45 0 Feb 28, 2024 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMCR Employee Share Option (Right to Buy) Options Exercise $0 -36.5K -11.84% $0.00 272K Feb 28, 2024 Ordinary Shares 36.5K $17.46 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 6, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.08 to $68.06 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.26 to $69.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.26 to $70.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.42 to $70.48 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 Immediately exercisable.